INTRODUCTION AND OBJECTIVES: Ductal carcinoma of the prostate (DCP) is a rare variant of prostate cancer. Consensus regarding the optimal treatment approach for patients with nonmetastatic DCP is currently lacking. We sought to assess national treatment trends for DCP and the impact of treatment selection on overall survival (OS).
METHODS: We queried the National Cancer Database to identify patients with non-metastatic DCP from [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] . Temporal trends in management were assessed. Differences in demographic and clinical factors between patients receiving radical prostatectomy (RP) or radiation therapy (RT) were assessed. Cox Proportional Hazard models were created to test the association of primary treatment selection with OS after adjustment for potential confounders. RESULTS: 1,312 patients were identified. There were 343 (26%) patients who underwent RT and 969 (74%) patients underwent RP. For each year of the study, more patients received RP than RT, and there was a trend toward increasing utilization of RP by 14% over the study period. Beam radiation and radioactive implants accounted for nearly 90% of the patients who received RT. Combinations of beam radiation with radioactive implants or radioisotopes were utilized in 24 (7%) of the patients. Table 1 compares the clinical and demographic factors between treatment groups. There was a total of 141 deaths, 58 (41%) from the RP group, and 83 (59%) from RT (p<0.01). The 5-year OS for the RP group was 93.5% (95% CI 0.91-0.95) vs. 78.8% (95% CI 0.73-0.83) for the RT group (p<0.01). Receipt of RT as primary therapy for DCP was associated with 3.69 times higher odds of death compared to patients who received RP (95% CI 2.46-5.52, p<0.01).
CONCLUSIONS: For men with DCP, primary therapy with RP improves overall survival compared with RT. Utilization of RP increased significantly from 2004-2015. The rate of selection of RT as initial management decreased during this time. This is the first study to report differential survival outcomes based on treatment selection in men with DCP.
INTRODUCTION AND OBJECTIVES: During radical prostatectomy cancer abutting or focally extending beyond the prostate capsule increases the risk of a positive surgical margin. Thus, intraoperative knowledge of the three-dimensional (3D) location of cancer can help the surgeon reducing this risk. We specifically developed an Elastic Augmented-Reality (AR) system based on elastic HyperAccuracy 3D reconstruction (HA3DTM), that simulates prostate deformation during the procedure. The aim of this study is to evaluate the accuracy of this 3D Elastic AR system in identifying capsular involvement (CI) of PCa during the NS phase of robot-assisted radical prostatectomy (RARP). METHODS: We prospectively enrolled patients with prostate cancer (cT1-3, cN0, cM0) undergoing RARP from May to September 2018. Preoperative mp-MRI was performed and CI was revealed. The PCa diagnosis was based on a positive target biopsy at the index lesion. The images in DICOM format were processed by software authorized for medical use by MEDICS Srl, in order to perform the HA3DTM. A dedicated software was developed in order to allow the deformation of 3D virtual images simulating the prostate deformation exercised by robotic arms during the intervention. Among the non parametric deformation we selected bend and stretch as those most suited to our visualization and overlay purposes. 3D reconstruction obtained was integrated in the robotic console to perform AR-RARP. During the nerve-sparing phase a mark (a metallic clip) was placed at prostate capsule at the level of suspicious CI.
RESULTS: 15 patients were enrolled. 16 lesions were identified at MRI. CI was confirmed at final pathology in 11 cases. At macroscopic evaluation the metallic clip was placed at the level of tumor and at level of suspicious capsule bulging in 16/16 (100%). Microscopic assessment was performed and confirmed cancer presence in 15/16 (93.7%) cases; moreover, CI was identified correctly in 11/11 (100.0%) cases.
CONCLUSIONS: 15 patients were enrolled. 16 lesions were identified at MRI. CI was confirmed at final pathology in 11 cases. At macroscopic evaluation the metallic clip was placed at the level of tumor and at level of suspicious capsule bulging in 16/16 (100%). Microscopic assessment was performed and confirmed cancer presence in 15/16 (93.7%) cases; moreover, CI was identified correctly in 11/11 (100.0%) cases.
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MP66-11 TRANSVESICAL ROBOT ASSISTED RADICAL PROSTATECTOMY
Gongxian Wang*, Xiaochen Zhou, Bin Fu, Cheng Zhang, Nanchang, China, People's Republic of INTRODUCTION AND OBJECTIVES: To introduce the technique and report our initial experience of transvesical robot assisted radical prostatectomy (TvRARP).
METHODS: 10 TvRARP for prostate cancer performed by a single surgical team between 2018 April and 2018 October were retrospectively reviewed. Preoperative data of patients [patient age (58.6AE9.4) years, BMI (26.5AE3.1) kg/m2, tPSA (19.5AE4.1) ng/ml, biopsy Gleason score 6(6w7), prostate volume (33.4AE15.8)ml and IIEF-5 score 12(10w16)] were collected. Preoperative study revealed 8 cases of cT1c, 1 case of cT2a and 1 case of cT2b. All patients were continent preoperatively. The surgery was performed with da Vinci Si system via 4 robotic ports and 2 assistant ports as the following: 1) cystotomy, further expended by bilateral suspension stitches. 2) A circumferential incision is made around the internal urethral orifice through the mucosa and muscular layer. 3) Initial dissection of the vas deferens and semi vesicles is carried out through the lower half of the circumferential incision around the internal urethral orifice. 4) Posterior dissection towards the apex of the prostate. 5) Dissection of bilateral NVB. 6) Anterior dissection towards the apex of the prostate. 7) Dissection and transection of the urethra. 8) Urethrovesical anastomosis. 9) 2-layer closure of bladder.
RESULTS: All 10 cases were successfully performed robotically without conversion, transfusion or other major intraoperative and postoperative complications. Postoperative pathology confirmed 6 pT2a cases, 3 pT2b cases and 1 pT2c case [Gleason score 6(6w7)]. 1 case reported positive surgical margin (10%). Operative time was (140.5AE35.5) min. Estimated blood loss was (65.5AE35.5) ml. Urethral catheter was removed at postoperative 7-day. 9 patients achieved urinary continence (0 pads) immediately after the removal of urinary catheter, while 1 patient returned to full continence in 2 weeks postoperatively. During a mean follow up of 3 months (2w4 months), no biochemical recurrence was noted (tPSA<0.2ng/ml). At 2-month postoperatively, IIEF-5 score was 11(8w13) and not statistically different from preoperative status (p > 0.05).
CONCLUSIONS: Transvesical approach is a valid alternative of performing RARP in patients bearing localized low-risk prostate cancer. Tumor control and preservation of erectile function remains to be determined in long term follow up.
